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Abstract
Compared to untreated opioid dependence, methadone maintenance treatment of opioid-dependent
pregnant women has been found to be associated with better maternal and neonatal outcomes.
Secondary analysis of data from 73 maternal and neonatal participants in the MOTHER study (H.
E. Jones et al., New England Journal of Medicine, 2010) found no relationship between maternal
methadone dose at delivery and any of 9 neonatal outcomes – peak neonatal abstinence syndrome
(NAS) score, total amount of morphine needed to treat NAS, duration of neonatal hospital stay,
duration of treatment for NAS, estimated gestational age at delivery, Apgar score at 5 minutes,
and neonatal head circumference, length, and weight at birth. These results are consistent with a
recent systematic review and meta-analysis (B. J. Cleary et al., Addiction, 2010) and extend
findings to outcomes other than NAS. Methodological and design issues that might have adversely
impacted the ability of researchers to establish the existence or non-existence of these
relationships are considered.
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1. Introduction
Methadone has been the most widely prescribed medication for the treatment of opioid
dependence during pregnancy (Jones et al., 2006). Research over the past four decades has
consistently supported its relative safety in the population of opioid-addicted pregnant
women, and it has been adopted worldwide as the standard of care in this population
(National Consensus Development Panel on Effective Medical Treatment of Opiate
Addiction, 1998). Methadone pharmacotherapy during pregnancy reduces the risk of fetal
exposure to the rapid and unpredictable cycles of highs and withdrawal and exposure to
other toxins associated with heroin use. Moreover, methadone pharmacotherapy has been
found to be superior to untreated heroin dependence on outcomes such as increasing the
likelihood of obstetrical care, improved fetal growth and decreasing the risks of fetal
mortality, HIV infection, and risk of preeclampsia [e.g., Finnegan (1991a,b); Jones et al.
(2006); Kaltenbach et al. (1998); Kandall et al. (1977); Schmid et al. (2010)]. Methadone
pharmacotherapy has also been found to be associated with superior treatment retention
(Finnegan et al., 1992; Jones et al., 2001; Jones et al., 2008; Laken et al., 1996; Svikis et al.,
1997) and less risk of relapse (Connaughton et al., 1977; Finnegan, 1991b; Jones et al.,
2008) relative to medication-free treatment.
There has been particular interest in the relationship between methadone dose and neonatal
outcomes for pregnant women in treatment for opioid dependence, as providers and patients
share the same goals of wanting to effectively treat the mother while minimizing potential
risks to the embryo and fetus. Higher maternal methadone dosing has been correlated with
improved treatment retention and less concomitant illicit drug use (McCarthy et al., 2005;
Seligman et al., 2010). Over the years, researchers have alternately found positive
correlations between higher maternal methadone dose and more severe neonatal abstinence
syndrome (NAS) [e.g., Dryden et al. (2009); Malpas et al. (1995); Wouldes et al. (2010)],
questioned the relationship (O’Grady et al., in press), or found no correlations between the
two variables [e.g., (Berghella et al. (2003); Pizarro et al. (2011); Seligman et al. (2010)].
These discrepant findings may be due to numerous methodological differences among the
studies and subject populations. Indeed, one of the major methodological differences among
the various studies is how ‘higher’ and ‘lower’ methadone dose has been defined. In many
cases, such a definition is sample-specific, and based on a median split, mean split, or some
form or low-medium-high division on methadone dose, typically at delivery or in the final
trimester [see (Cleary et al., 2010) for various categorizations that have occurred in the
published literature]. Such a course of action leads one study (Strauss et al., 1976) to define
‘low’ and ‘high’ dose groups as less than or equal to 20 mg or more than 20 mg methadone,
respectively, while a second study (McCarthy et al., 2005) divides their sample into ‘low’ at
less than 100 mg and ‘high’ at 100 mg or more of methadone. The interpretation of the
impact of ‘higher’ doses of methadone then becomes problematic, and the comparison of the
results across these studies then becomes virtually meaningless. Despite these significant
limitations, a recent systematic literature review (Cleary et al., 2010) and meta-analysis of
29 studies that examined the relationship between maternal methadone dose and NAS from
1966-2009 concluded that when the analyses were limited either to prospective studies or to
studies in which the measurement of NAS was conducted with a valid measure, the “severity
of the NAS does not appear to differ according to whether mothers are on high- or low-dose
methadone maintenance therapy” (p. 2071).
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Although less frequent, other research has examined the relationship between maternal
methadone dose and neonatal outcomes other than NAS. Velez et al. (2009) found that
maternal methadone dose was not correlated with scores on the NICU Network
Neurobehavioral scale, a comprehensive measure of neurobehavioral functioning, in a
sample of 77 infants. Gray et al. (2010) reported no relationship between maternal
methadone dose at delivery and gestational age at birth, need for pharmacotherapy for NAS,
peak NAS score, or birth parameters in a sample of 49 opioid-dependent pregnant women.
The Maternal Opioid Treatment: Human Experimental Research (MOTHER) study (Jones et
al., 2010) examined maternal and neonatal clinical outcomes in a sample of 175 (131 of
whom completed the trial and gave birth while maintained on study medication) opioid-
dependent pregnant women participating in a randomized clinical trial comparing
methadone and buprenorphine. The MOTHER study is unique in several respects, notably
because exclusionary criteria required participants to have no current abuse or dependence
of either alcohol or benzodiazepines. Moreover, a contingency management approach in
which patients earned monetary vouchers for providing urine samples negative for opioids
and other illicit drugs was used in order to ensure that the participants maintained their drug-
free status, which led to an extremely low level of use of concomitant drugs throughout the
study that might have served to contaminate the relationship between maternal methadone
dose levels and neonatal clinical outcomes.
The purpose of the present paper is twofold. The first purpose was to examine the
relationship between methadone dose and neonatal clinical outcomes in the sample of 73
opioid-dependent pregnant women receiving methadone pharmacotherapy who participated
in the MOTHER study. The second purpose was to examine differences in the neonatal
outcomes between the neonates of these methadone-maintained participants who were
(n=41) and were not (n=32) treated for NAS with morphine sulfate. Given the low level of
use of concomitant drugs used by participants in MOTHER and the fact that the participants
were provided with financial incentives to remain drug-free, data from the MOTHER study
allow for an examination of these two issues, largely in the absence of poly-substance use on
the part of the participants. Moreover, data from the MOTHER study has the advantage over
most retrospective studies, as well as many prospective studies, in that the measurement of
NAS was conducted by well-trained raters in a uniform manner and found to be highly
reliable. Thus, the MOTHER study allows for an estimate of the relationship between
methadone dose and neonatal clinical outcomes, unconfounded by other drugs of abuse, and
for the estimation of differences between NAS treatment status (neonates untreated v.
treated for NAS) on these same outcomes.
2. Methods
2.1 The MOTHER Study
The Maternal Opioid Treatment: Human Experimental Research (MOTHER) study (Jones et
al., 2012; Jones et al., 2010) was a double-blind, double-dummy (i.e., both conditions
received their respective medication and a placebo), flexible-dosing, parallel-group
randomized clinical trial that provided comprehensive care to 175 opioid-dependent
pregnant women who were given either methadone or buprenorphine. Results indicated that
buprenorphine-exposed neonates required, on average, 89% less morphine to treat NAS,
spent, on average, 43% less time in the hospital and, 58% less time in the hospital being
medicated for NAS than did the methadone-exposed neonates.
Complete details regarding the study can be found in Jones et al. (2012) and Jones et al.
(2010). The following information provides an overview of the study germane to the present
secondary analyses.
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Neonatal outcome data were collected at 7 university hospital sites. However, sites were
combined into three categories because the number of participants at some US sites was
relatively small, and pooling the sites for the purposes of statistical analysis minimized the
possibility that site heterogeneity due to small samples sizes might adversely impact the
analyses: US Urban (Baltimore, MD; Philadelphia, PA: Detroit MI: Providence, RI) v. US
Rural (Burlington, VT; Nashville, TN) v. European (Vienna).
2.3 MOTHER Participants
Opioid-dependent, singleton pregnant (6-30 weeks gestation) women meeting eligibility
criteria were recruited. Participants were randomized to methadone or buprenorphine and
received double-blind, double-dummy, study medication administered daily with sublingual
tablets (buprenorphine or placebo) followed by oral liquid (methadone or placebo). A
flexible dose range of 20 to 140 mg of methadone was used in the methadone condition. To
reduce concomitant drug use, patients earned monetary vouchers for providing urine
samples thrice weekly that tested negative for other non-prescribed opioids and other illicit
drugs. Of the 175 maternal participants, 131 delivered infants as part of the study, and of
these 131, 73 were in the methadone condition with 41 neonates treated for NAS with
morphine sulfate, and 32 infants receiving no pharmacotherapy for NAS. The secondary
analyses reported in this paper use the data from the neonates of these 73 maternal
participants.
2.4 MOTHER Measures of Interest
A modified Finnegan Scale (Finnegan et al., 1992) (MOTHER NAS Scale) was
administered for a minimum of 10 days by trained staff to assess neonatal abstinence
syndrome (NAS). The MOTHER NAS scale has a total of 28 items, with 19 items used for
scoring and medication decisions. The maximum withdrawal score on the MOTHER NAS
Scale is 42. A NAS peak score was derived for each neonate, representing the highest NAS
score the neonate obtained within the first 10 days after birth. The degree of agreement on
NAS scale measures of the site raters and the expert rater who trained the site raters was
assessed every 6 months and was evaluated by an intraclass correlation [ICC(2,2)], which
exceeded .94. The protocol specified that babies were to receive NAS observations for the
first 10 postpartum days, regardless of NAS treatment. Hospital regulations did not allow
some sites to keep non-treated babies in the hospital for more than 4 days. Thus, those
babies received their multiple NAS observations on an outpatient basis. Neonates requiring
pharmacotherapy for NAS were treated with morphine sulfate as inpatients for the duration
of their therapy (Jones et al., 2012).
Information was also collected during the course of the trial on medication dose at delivery
(mg), and 8 additional measures of interest to the present study: total amount of morphine
needed to treat NAS (mg), duration of neonatal hospital stay (days), duration of treatment
for NAS (days), estimated gestational age at delivery (weeks), Apgar score at 5 minutes, and
neonatal head circumference (cm), length (cm), and weight (gm) at birth. [Apgar score at 1
minute was also collected and reported in Jones et al. (2010). Given the general conclusion
that 1-minute Apgar scores are not predictive of neonatal future outcome (American
Academy of Pediatrics Committee on Fetus and Newborn, 2006) an analysis of this variable
is omitted from the current paper.]
2.5 Statistical Analyses
Because our assumption was that the following outcome variables were normally
distributed, ordinary least squares regression analyses (Draper et al., 1998) were conducted
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for: Peak score on the MOTHER NAS scale during the assessment period, and infant head
circumference, birth weight, and length. In contrast, our assumption was that the following
outcomes followed a Poisson distribution in the population, so a Poisson regression model
using Laplace approximation (Littell, 2006) was utilized for: Total amount of morphine
needed to treat NAS (measured in mg), number of days medicated for NAS (days), duration
of neonatal hospital stay (days), estimated gestational age at delivery (weeks), and Apgar
scores at 5 minutes. The Poisson regression model included a random intercept term and an
overdispersion parameter. In each Poisson regression analysis, the overdispersion parameter
was tested for significance, and if it was not significant, the model was re-fitted omitting the
dispersion parameter. (Laplace estimation was chosen because it generally shows better
asymptotic behavior and less bias in small samples than does pseudo-likelihood estimation.)
Predictor variables in all models included a three-level fixed site factor. For those analyses
that estimated the relationship between methadone dose at delivery and neonatal clinical
outcomes, methadone dose at delivery was included as a continuous predictor as the primary
effect of interest. For those analyses that examined the differences between NAS treatment
status and neonatal clinical outcomes, a fixed effect representing NAS treatment status
(untreated v. treated with morphine sulfate) was included in the statistical model as the
primary effect of interest. NAS treatment status was necessarily only examined for 7
neonatal clinical outcomes, given that total amount of morphine needed to treat NAS and
number of days medicated for NAS were, by definition, all zero in the group of neonates
untreated for NAS. Unstandardized partial regression coefficients (b weights) and their
standard errors are reported for the results for methadone dose, while model-derived
estimated means are reported for NAS treatment status.
More complete details about MOTHER measures and statistical methods can be found in
(Jones et al., 2010).
3. Results
Mean methadone dose at delivery was 84.9 mg (SD=35.3; range 20-140). Descriptive
statistics for the 9 outcome measures can be found in Table 1.
3.1 Relationship between Methadone Dose and Neonatal Outcomes
Results for the analyses of the 9 outcomes failed to reject the null hypothesis of no
relationship between methadone dose and the respective outcome measure (all ps>.05).
Parameter estimates and their standard errors for these analyses can be found in Table 2.
However, all Poisson regression adjusted odds ratio (AOR) estimates are quite close to 1,
suggesting the possibility that the statistical model was more complex than the data would
allow for the 5 outcome variables assumed to follow a Poisson distribution. Because
research has suggested that an overdispersed Poisson model can sometimes better be
modeled as a negative binomial process, the analyses of these 5 variables were also
conducted under the assumption that the outcome variable in question followed a negative
binomial distribution in the population. Results indicated a failure to reject the null
hypothesis (all ps > .09). As with the Poisson regression model, parameter estimates for the
negative binomial model were again quite close to 1, with narrow confidence intervals. In a
final attempt to further simplify the statistical model, at the expense of the distributional
assumption, the relationship between methadone dose at delivery and these 5 outcome
measures was examined in an ordinary least squares regression model, with the same result
(all ps > .17).
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Finally, only 41/73 neonates were treated for NAS, and so 32 neonates necessarily had
scores of 0 for total amount of morphine needed to treat NAS and number of days treated for
NAS (hence the need for an overdispersed Poisson model). Both Poisson and negative
binomial regression analyses for these two outcome variables that included observations
only from these 41 neonates treated for NAS found no relationship between methadone dose
at delivery and either outcome (all ps > .4).
3.2 Relationship between NAS Treatment Status and Neonatal Outcomes
For those infants treated for NAS, the mean total amount of morphine for NAS (mg) was
33.7 (SD=64.8), with the mean dose of morphine per kg of body weight at the initiation of
treatment for NAS equal to 0.028 (SD=0.022) and the mean highest dose of morphine per kg
of body weight equal to 0.032 (SD=0.030). The mean duration of treatment for NAS (days)
was 21.7 (SD=17.9). (One case is missing data for these outcomes due to neonatal demise.)
Table 3 presents descriptive statistics for the 7 remaining outcomes in the untreated (n=32)
and treated (n=41) for NAS groups. Significant mean differences were found between these
two groups for duration of neonatal hospital stay, F(1, 69) = 19.7, p < .001, [M = 9.8 days
(SE = 2.1) v. M = 23.5 days (SE = 2.4), respectively], NAS peak score, F(1, 68) = 71.4, p < .
001, [M = 8.1 (SE = 0.7) v. M = 16.1 (SE = 0.6), respectively], and neonatal weight at birth,
F(1, 69) = 4.7, p < .04, [M = 2735.8 gm (SE = 96.6) v. M = 3015.9 gm (SE = 87.3),
respectively]. All other tests of mean differences between the NAS treatment status groups
were nonsignificant (all ps > .07).
4. Discussion
Findings of the present study, in need of confirmation by future prospective studies, extend
the reach of the recent systematic review (Cleary et al., 2010) beyond the scope of NAS, and
replicate and extend the findings of Gray et al. (2010). The failure to find any support for a
relationship between maternal methadone dose at delivery and the 9 neonatal clinical
outcomes was examined in the context in which the Type I error rate was set at .05,
maximizing our chances of rejecting H0 and therefore finding support for a relationship
between maternal methadone dose at delivery and any one or more of the neonatal clinical
outcomes.
Furthermore, the relationship between methadone dose and 5 of the neonatal outcomes were
tested under a variety of distributional assumptions for these variables. Despite such a liberal
approach to hypothesis testing, no support was found for a relationship between methadone
dose and neonatal outcomes for any 1 of the 9 variables. Moreover, it should be noted that
this failure to reject any 1 of the 9 null hypotheses occurred in a sample of women who were
not abusing, in any significant way, other substances that could serve to either mask or boost
a relationship between the variables in question. In other words, testing 9 interdependent
hypotheses in a way that favored rejection of one or more null hypotheses failed to yield a
significant finding. Taken together, these findings suggest that there is likely no relationship
between maternal methadone dose at delivery and any of several clinically important
neonatal outcomes, including NAS severity.
It is reasonable at this point to ask why there are findings in the literature contrary to this
conclusion, as noted in the introduction. There is, of course, the obvious ‘first’ conclusion
that the studies in question represent Type I error. Certainly this is a possibility for some
studies, but such a conclusion is both too quick and likely too simplistic. It is probable there
are several factors operating that have contributed (and perhaps will continue to contribute)
to this confusion. First, it is quite possible that there are differences in the populations from
which the samples have been drawn. There may be geographical differences in the maternal
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and infant subjects and drug use patterns, and in local treatment clinic practices that might
lead to differences in the population of opioid-dependent pregnant women seeking
treatment, and/or the extent and nature of treatment provided to them. Optimal treatment for
opioid-dependent pregnant women offers methadone pharmacotherapy in the context of
comprehensive care including obstetric care and drug treatment; however, such care is not
always available, particularly in rural areas. The combination of different populations
seeking treatment for different reasons and being provided different treatments could
certainly operate to either ameliorate or amplify the relationship between maternal
methadone dose at delivery and neonatal outcomes.
Second, there is the obvious issue of how maternal methadone dose at delivery has been
defined by the various researchers in this area that has likely impeded the ability to
determine whether there is any relationship between maternal methadone dose at delivery
and outcome. Researchers have ‘crudely classified observations’, dividing their samples into
low and high groups by methods such as the median split, as noted in the Introduction. Such
classification schemes are ad hoc, and greatly impede the ability of reviewers and
researchers to compare results across studies. Moreover, as Cohen (1983) has convincingly
shown: “Assuming bivariate normality with correlation r, dichotomizing one variable at the
mean results in the reduction in variance accounted for to .647r2 …” resulting in “reduction
in statistical power equivalent to discarding 38% … of the cases under representative
conditions” (p. 249). Barring some compelling argument for an exception to this conclusion,
the only reasonable approach would be to treat maternal methadone dose at delivery as a
continuous variable, and correlate it with the outcome variable(s). Such an approach has the
added virtue of answering the question of whether or not there is a dose-response
relationship between methadone and the outcome(s) of interest, and estimating the rate of
change associated with this relationship.
Third, there is neither standardized assessment for NAS measurement nor its treatment.
NAS measurement is highly variable, both between tools and in use of the same tool, and
depends on subjective assessments by a variety of assessors with variable levels of skill and/
or experience with substance exposed infants. The potential interchangeability among
different tools has not been examined. NAS treatment is also widely variable, with variable
non-pharmacologic measures applied or not applied, different medications used, and
different dosing strategies employed. All of these factors likely lead to differences in
statistical conclusion validity among the studies that have utilized them.
Fourth, there is no evidence that maternal dose of methadone correlates with other biological
samples germane to this discussion, which may help to explain the fact that maternal
methadone dose at delivery is not the strong predictor of neonatal clinic outcomes as might
first have been thought. Maternal dose did not correlate with maternal serum concentrations
of methadone in a sample of recently postpartum women (Jansson et al., 2007). The lack of
a significant relationship between maternal methadone dose and meconium concentrations
of methadone and its metabolites and NAS severity (Gray et al., 2010; Kuschel et al., 2004)
suggests that neonates differ in the rate of elimination of methadone from their systems.
Metabolism of methadone by the placenta (Nanovskaya et al., 2004), fetus (Kuschel et al.,
2004), and infant (Rosen et al., 1976) are likely to play a role in the variable expression of
NAS among opioid-exposed infants, and may additionally be affected by other factors such
as genetics (Oei et al., 2012), although the nature of these relationships have yet to be fully
elucidated.
Finally, it is imperative to note that methadone, like any medication given during the
perinatal period, has risks and benefits. Results of the present study do not lend support to
the contention that limiting the dose of methadone to treat pregnant women will reduce the
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possibility of poor neonatal outcomes. Indeed, such a position contradicts national clinical
guidelines [e.g., Center for Substance Abuse Treatment. (2005); New South Wales
Department of Health, (2006)] and may create unintended yet harmful radiating effects for
the mother, the fetus, and the neonate.
The findings that the group treated for NAS had a higher mean NAS peak score and spent a
longer time in the hospital on average than did the group not treated for NAS are hardly
surprising. Both of these outcomes are likely the result, in large part, of the need for NAS
treatment. The finding that the untreated group weighed less at birth than the treated group is
likewise unsurprising, given it had been reported in a study predicting NAS treatment in the
entire MOTHER sample (Kaltenbach et al., 2012). It should be noted that the ratio of
females:males and preterm:term for the two groups was roughly equivalent, so this result is
not due to differences in gender or prematurity in the two groups. Certainly this finding
merits attention in future research.
4.1 Limitations
There is the clear concern that the present study is based on a relatively small sample of
women who are atypical of the majority of opioid-dependent pregnant women in methadone
pharmacotherapy. For example, Dryden and colleagues (Dryden et al., 2009) found a
positive relationship between methadone dose and NAS incidence in a retrospective study of
444 methadone-maintained women. However, many of the Dryden et al. participants were
poly-substance-using, and 93% of the neonates receiving pharmacotherapy for NAS had
been exposed to prenatal poly-substance abuse. In contrast, the MOTHER sample showed
no current abuse or dependence of either alcohol or benzodiazepines and generally used
cocaine and other drugs at low levels, if at all. Moreover, participants were offered financial
incentives to remain drug-free throughout their time in the study. Thus, the extent to which
findings from the present study generalize to the larger population of opioid-dependent
pregnant women in methadone pharmacotherapy is unknown, and requires further
investigation. However, it is also the case that the present sample allows for the examination
of the relationship between methadone dose and neonatal outcomes without the potentially
confounding factor of poly-substance use.
4.2 Conclusions
Opioid dependence rarely occurs in the absence of confounding bio-psycho-social issues.
Thus, the effects of any drug or medication – including methadone – on mothers and infants
are best understood in the context of complex life challenges that most opioid-dependent
pregnant patients face and other exposures (i.e. other licit or illicit medications/drugs,
nicotine, alcohol, maternal stress, etc.) that the fetus experiences. The field would be best
served by future research focused on understanding and ameliorating the underlying factors
which lead women to initiate and maintain drug use, and the roles such factors might play in
both maternal and neonatal response to medications and their longer-term outcomes.
Understanding such factors could allow more focused and specific treatment for the highly
complex and vulnerable population of opioid-dependent women and their children.
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• We conducted secondary analyses of MOTHER data (H. E. Jones et al., New
England Journal of Medicine, 2010).
• These analyses found no relationship between maternal methadone dose and 9
neonatal outcomes.
• The conclusion of a methadone dose-response relationship with neonatal
outcomes is unwarranted.
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Table 1
Descriptive Statistics for the 9 Neonatal Clinical Outcomes from the MOTHER Methadone Condition
participants (N=73)
Variable M SD Range
Total amount of morphine for NAS
†
 (mg) 19.2 51.5 0 – 354.5
Duration of treatment for NAS
†
 (days) 12.3 17.2 0 – 76
Duration of neonatal hospital stay (days) 18.3 17.2 2 – 79
Gestational age at delivery (weeks) 38.0 2.3 32 – 41
Apgar score at 5 minutes 8.9 1.0 5 – 10
Peak NAS score
† 12.8 5.5 3 – 26
Neonatal weight at birth (gm) 2880.0 546.1 1440 – 3742
Neonatal length at birth (cm)
† 47.8 4.6 20 – 54
Neonatal head circumference at birth (cm)
† 33.0 2.1 24 – 36
Notes. NAS = Neonatal Abstinence Syndrome. Means do not equal values found in Table 2 of Jones et al. (2010), because the latter means were
model-derived marginal means from a model that includes the buprenorphine condition, and were adjusted for site.
†
One case is missing data for this variable due to neonatal demise.
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Table 2
Estimates from the Regression Analyses Examining the Relationship between Methadone Dose and 9
Neonatal Clinical Outcomes from the MOTHER Methadone Condition participants (N=73)
Outcome Variable b SE AOR 95% CI P




.01 .01 1.01 1.00, 1.03 .09
Duration of treatment for NAS
†
(days)
.01 .01 1.01 1.00, 1.03 .051
Duration of neonatal hospital
stay (days) .00 .00 1.00 1.00, 1.01 .14
Gestational age at delivery
(weeks) .00 .00 1.00 1.00, 1.00 .84
Apgar score at 5 minutes .00 .00 1.00 1.00, 1.00 .86
NAS peak score
† .04 .02 .07
Neonatal head circumference at
birth (cm)
† .00 .01 .80
Neonatal weight at birth (gm) 1.55 2.12 .47
Neonatal length at birth (cm)
† .01 .01 .57
Notes. Predictor variables included maternal methadone dose at delivery (mg) and a three-level fixed site factor. NAS = Neonatal Abstinence
Syndrome. SE = Standard Error. AOR = Adjusted Odds Ratio (adjusted for the fixed site factor). 95% CI = 95% Confidence Interval. Estimates for
Total amount of morphine for NAS and Duration of treatment for NAS were derived from an overdispersed Poisson regression model, while
estimates for Duration of neonatal stay, Gestational age at delivery, and Apgar scores at 5 minutes were derived for a Poisson regression model that
omitted the overdispersion term, because the test of the need for an overdispersion parameter was nonsignificant for these 3 outcomes. Estimates
for NAS peak score and neonatal head circumference, weight, and length at birth were derived from ordinary least squares regression.
†
One case is missing data for this variable due to neonatal demise.
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Table 3
Model-derived Estimated Means and Standard Errors for the 7 Neonatal Clinical Outcomes from the






Outcome Variable M SE M SE P
Duration of neonatal hospital stay (days) 23.5 2.4 9.8 2.1 < .001
Gestational age at delivery (weeks) 38.2 1.0 37.8 1.1 .75
Apgar score at 5 minutes 9.0 0.5 8.9 0.5 .98
Peak NAS score
† 16.1 0.6 8.1 0.7 < .001
Neonatal weight at birth (gm) 3015.9 87.3 2735.8 96.6 .04
Neonatal length at birth (cm)
† 48.8 0.7 46.7 0.8 .07
Neonatal head circumference at birth (cm)
† 33.4 0.3 32.6 0.4 .15
Notes. Predictor variables in the model included a fixed effect represented NAS treatment status and a three-level fixed site factor. NAS = Neonatal
Abstinence Syndrome. M = Model-derived estimated mean. (Means are adjusted for the fixed site factor.) SE = Standard Error.Means for Duration
of neonatal stay, Gestational age at delivery, and Apgar scores at 5 minutes were derived for a Poisson regression model that omitted an
overdispersion term, because the test of the need for an overdispersion parameter was nonsignificant for these 3 outcomes. The estimates for NAS
peak score and neonatal head circumference, weight, and length at birth were derived from ordinary least squares regression.
†
One case is missing data for this variable due to neonatal demise.
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